Migraine Minute News Update

May 31 2024 2

Migraine Minute News Update Podcast artwork

The Migraine Minute provides weekly updates in migraine research and news hosted by Molly O'Brien of the Association of Migraine Disorders.

Subscribe on Podcast Addict

Can This Gepant be an Effective Preventive Treatment Option for Tough to Treat Episodic Migraine?

A study in the Lancet found one oral gepant to be safe and effective in people with episodic migraine who have failed two to four classes of preventive treatments. Molly O’Brien explains in this Migraine Minute News Update. Read the study here: https://bit.ly/3w3ZM45

Comparing Anti-CGRP monoclonal antibodies to OnabotulinumtoxinA for chronic migraine

May 17 2024 1 mins

A new study looks at real-word effectiveness of Anti-CGRP monoclonal antibodies & OnabotulinumtoxinA for chronic migraine. Molly O'Brien will share the study findings in this Migraine Minute News update. Read the study: https://bit.ly/4d1mPx1 *The graphic used in this content is courtesy of Grazzi, L., Giossi, R., Montisano, D.A. et al. Real-world effectiveness of Anti-CGRP monocl

Can blood flow changes in the eyes explain visual migraine symptoms?

Researchers at the University of California Los Angeles found changes in blood flow in the retina might explain why some people have visual migraine symptoms. Molly O'Brien has the details in this Migraine Minute News update. Learn more: https://bit.ly/3xou7uw , https://bit.ly/4aErYZN

Exclusive! A First Look at Survey Results From the HEADS Registry

Apr 22 2024 1 mins

AMD is thrilled to share what we’ve learned so far from our HEADS Registry! Molly O'Brien goes over the exclusive new data in this Migraine Minute News Update. The HEADS Registry serves as a crucial resource for researchers and clinicians. It’s not too late to share your experience, by doing so, you can help pave the way for more effective therapies, enhanced and personalized

Migraine Minute News Update: One CGRP MAB Drug May Reduce Migraine Attacks in Adults with Obesity

Obesity is often connected with an increase in migraine frequency, severity and disability. In this Migraine Minute News Update, Molly O'Brien gives details on what we’re learning about one MAB drug and its effectiveness in people with migraine and comorbid obesity. Read more here: https://bit.ly/3ONRu6m

Migraine Minute News Update: Is there a link between migraine stigma and quality of life?

New results from the OVERCOME study, published in Neurology, Found that just over 31 percent of people living with migraine often or very often feel stigmatized. Molly O'Brien will fill you in on the details in this Migraine Minute News Update.

One Drug-Free Migraine Treatment Becomes First To Get Commercial Insurance Coverage

Nerivio becomes the first drug-free Migraine Treatment to Receive Commercial Insurance Coverage in the US. Molly O'Brien explains in this Migraine Minute News Update. Read more here: https://bit.ly/3T6lKvL

What Do We Know About Migraine and ADHD Symptoms?

We know Migraine and ADHD are comorbid, but there is still a lot left to learn about how they are connected. @Molly O’Brien will fill you in on new research that explores ADHD symptoms in people with migraine. Sources: https://bit.ly/3vNm6hT

Migraine Minute News Update: These 3 Drugs May Be More Effective Than Ibuprofen for Migraine Treatment

Jan 26 2024 1 mins

Feel a migraine attack coming on? New research shows these three types of medications may be more effective than ibuprofen for many people. Molly O’Brien will share details in this Migraine Minute News Update. Read more here: https://bit.ly/47HEwh9

Migraine Minute News Update: Taking this drug during the migraine prodrome may help prevent severe headache.

New research shows taking one type of gepant medication during the prodrome phase may reduce the risk of a severe headache. Molly O’Brien will fill you in, in this Migraine Minute News Update. Read the study here: https://bit.ly/3GLKEtT